




PHARMACEUTICAL 2023

Paratek Pharmaceuticals Inc.
Rank 376 of 446





RealRate

PHARMACEUTICAL 2023

Paratek Pharmaceuticals Inc. Rank 376 of 446



The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 160% points.

The company's Economic Capital Ratio, given in the ranking table, is -139%, being 182% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	136,842
Cost of Goods Sold	23,056
Intangible Assets	829
Liabilities, Current	37,388
Liabilities, Non-Current	260,867
Other Assets	34,251
Other Compr. Net Income	9.0
Other Expenses	18,176
Other Liabilities	45,325
Other Net Income	819
Other Revenues	160,268
Property and Equipment	616
Research and Development	37,823
Selling, General and Administrative Expense	145,598

Output Variable	Value in 1000 USD
Assets	172,538
Liabilities	343,580
Expenses	224,653
Revenues	160,268
Stockholders Equity	-171,042
Net Income	-63,566
Comprehensive Net Income	-63,562
Economic Capital Ratio	-139%